Cited 5 times in
Full-dose gemcitabine is a more effective chemotherapeutic agent than 5-fluorouracil for concurrent chemoradiotherapy as first-line treatment in locally advanced pancreatic cancer
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 박승우 | - |
dc.contributor.author | 박정엽 | - |
dc.contributor.author | 방승민 | - |
dc.contributor.author | 성진실 | - |
dc.contributor.author | 송시영 | - |
dc.contributor.author | 오탁근 | - |
dc.contributor.author | 정문재 | - |
dc.contributor.author | 정재복 | - |
dc.contributor.author | 강화평 | - |
dc.contributor.author | 장지석 | - |
dc.date.accessioned | 2016-02-04T11:11:49Z | - |
dc.date.available | 2016-02-04T11:11:49Z | - |
dc.date.issued | 2014 | - |
dc.identifier.issn | 0009-3157 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/139881 | - |
dc.description.abstract | OBJECTIVES: To compare the efficacy of full-dose gemcitabine-based concurrent chemoradiotherapy (FG-CCRT) and conventional 5-fluorouracil CCRT (5FU-CCRT) for locally advanced pancreatic cancer (LAPC). METHODS: 109 LAPC cases treated with FG-CCRT (n = 89) or 5FU-CCRT (n = 20) were reviewed retrospectively. The FG-CCRT group was composed of a full-dose gemcitabine monotherapy (1,000 mg/m(2)) arm and a combination therapy with cisplatin (70 mg/m(2)) arm. The 5FU-CCRT group used a radiosensitizing dose of 5-FU (500 mg/m(2)) plus leucovorin (20 mg/m(2)). Concurrent radiotherapy was targeted at the tumor with a 5-mm margin without lymph node irradiation. RESULTS: Objective response rate (ORR) and disease control rate (DCR) was significantly higher in the FG-CCRT group (ORR: 32.6 vs. 5%, p = 0.013; DCR: 79.8 vs. 50.0%, p = 0.006). FG-CCRT showed remarkable superiority to 5FU-CCRT for suppressing distant metastasis (18.0 vs. 45.0%, p = 0.017). Neutropenia (34.8 vs. 10%, p = 0.032) and thrombocytopenia (21.3 vs. 0.0%, p = 0.021) were more frequent in the FG-CCRT group as originally expected. When dividing the FG-CCRT group to gemcitabine monotherapy (GEM) and gemcitabine plus cisplatin, toxicities of the GEM subgroup were not different than those of the 5FU-CCRT group. CONCLUSION: FG-CCRT, especially full-dose gemcitabine monotherapy-based CCRT was more effective for the initial control of LAPC than 5FU-CCRT, and also relatively safe. | - |
dc.description.statementOfResponsibility | open | - |
dc.relation.isPartOf | CHEMOTHERAPY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Adult | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Aged, 80 and over | - |
dc.subject.MESH | Antineoplastic Agents/administration & dosage | - |
dc.subject.MESH | Antineoplastic Combined Chemotherapy Protocols/therapeutic use* | - |
dc.subject.MESH | Chemoradiotherapy/methods | - |
dc.subject.MESH | Cisplatin/administration & dosage | - |
dc.subject.MESH | Combined Modality Therapy/methods | - |
dc.subject.MESH | Deoxycytidine/administration & dosage | - |
dc.subject.MESH | Deoxycytidine/analogs & derivatives | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Fluorouracil/administration & dosage | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Leucovorin/administration & dosage | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Pancreatic Neoplasms/therapy* | - |
dc.subject.MESH | Retrospective Studies | - |
dc.title | Full-dose gemcitabine is a more effective chemotherapeutic agent than 5-fluorouracil for concurrent chemoradiotherapy as first-line treatment in locally advanced pancreatic cancer | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학) | - |
dc.contributor.googleauthor | Kang H. | - |
dc.contributor.googleauthor | Chang J.S. | - |
dc.contributor.googleauthor | Oh T.G. | - |
dc.contributor.googleauthor | Chung M.J. | - |
dc.contributor.googleauthor | Park J.Y. | - |
dc.contributor.googleauthor | Park S.W. | - |
dc.contributor.googleauthor | Seong J. | - |
dc.contributor.googleauthor | Song S.Y. | - |
dc.contributor.googleauthor | Chung J.B. | - |
dc.contributor.googleauthor | Bang S | - |
dc.identifier.doi | 10.1159/000375402 | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A01551 | - |
dc.contributor.localId | A01647 | - |
dc.contributor.localId | A01786 | - |
dc.contributor.localId | A01956 | - |
dc.contributor.localId | A02035 | - |
dc.contributor.localId | A02410 | - |
dc.contributor.localId | A03602 | - |
dc.contributor.localId | A03706 | - |
dc.contributor.localId | A00100 | - |
dc.contributor.localId | A04658 | - |
dc.relation.journalcode | J00519 | - |
dc.identifier.eissn | 1421-9794 | - |
dc.identifier.pmid | 25824121 | - |
dc.identifier.url | http://www.karger.com/Article/FullText/375402 | - |
dc.subject.keyword | Locally advanced pancreatic cancer | - |
dc.subject.keyword | Chemoradiotherapy | - |
dc.subject.keyword | Concurrent chemoradiotherapy | - |
dc.subject.keyword | Gemcitabine | - |
dc.subject.keyword | 5-fluorouracil | - |
dc.contributor.alternativeName | Park, Seung Woo | - |
dc.contributor.alternativeName | Park, Jeong Youp | - |
dc.contributor.alternativeName | Bang, Seung Min | - |
dc.contributor.alternativeName | Seong, Jin Sil | - |
dc.contributor.alternativeName | Song, Si Young | - |
dc.contributor.alternativeName | Oh, Tak Geun | - |
dc.contributor.alternativeName | Chung, Moon Jae | - |
dc.contributor.alternativeName | Chung, Jae Bock | - |
dc.contributor.alternativeName | Kang, Hwa Pyoung | - |
dc.contributor.affiliatedAuthor | Park, Seung Woo | - |
dc.contributor.affiliatedAuthor | Park, Jeong Youp | - |
dc.contributor.affiliatedAuthor | Bang, Seung Min | - |
dc.contributor.affiliatedAuthor | Seong, Jin Sil | - |
dc.contributor.affiliatedAuthor | Song, Si Young | - |
dc.contributor.affiliatedAuthor | Oh, Tak Geun | - |
dc.contributor.affiliatedAuthor | Chung, Moon Jae | - |
dc.contributor.affiliatedAuthor | Chung, Jae Bock | - |
dc.contributor.affiliatedAuthor | Kang, Hwa Pyoung | - |
dc.rights.accessRights | not free | - |
dc.citation.volume | 60 | - |
dc.citation.number | 3 | - |
dc.citation.startPage | 191 | - |
dc.citation.endPage | 199 | - |
dc.identifier.bibliographicCitation | CHEMOTHERAPY, Vol.60(3) : 191-199, 2014 | - |
dc.identifier.rimsid | 46618 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.